<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Orgenesis Inc.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:9c6e0763-ea89-4409-949f-84d102de6643;id=9722</id> <rights type="text">Copyright 2024, Orgenesis Inc.</rights> <updated>2024-11-13T13:00:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/6aPLgkFozRDIrmRb4UCY4A==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/6aPLgkFozRDIrmRb4UCY4A==" /> <entry> <id>https://www.globenewswire.com/news-release/2024/11/13/2980212/24226/en/Orgenesis-Provides-Third-Quarter-2024-Business-Update.html</id> <title type="text">Orgenesis Provides Third Quarter 2024 Business Update</title> <published>2024-11-13T13:00:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/13/2980212/24226/en/Orgenesis-Provides-Third-Quarter-2024-Business-Update.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=_U6CjYLot0iVn3OxJcCvHl4zkN-JZJDiuo-kTk9n1_VScL_oiXCQ7GRBaxAQFeTPcWK7QQZ83fzrLXn3lnsFxQ==" rel="nofollow" target="_blank" title=""><strong>Orgenesis Inc</strong></a><strong>. (</strong><strong>OTCQ</strong><strong>X</strong><strong>: ORGS)</strong> (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024.</p>]]></content> <dc:identifier>2980212</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Wed, 13 Nov 2024 13:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/21/2966164/24226/en/Orgenesis-Commences-Trading-on-OTCQX-Best-Market.html</id> <title type="text">Orgenesis Commences Trading on OTCQX® Best Market</title> <published>2024-10-21T12:00:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/21/2966164/24226/en/Orgenesis-Commences-Trading-on-OTCQX-Best-Market.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center"><em>Reports Plans to Reapply for Nasdaq Listing</em></p>]]></content> <dc:identifier>2966164</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Mon, 21 Oct 2024 12:01 GMT</dc:modified> <dc:subject>Stock Market News</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/23/2951240/24226/en/Orgenesis-Announces-Reverse-Stock-Split.html</id> <title type="text">Orgenesis Announces Reverse Stock Split</title> <published>2024-09-23T11:00:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/23/2951240/24226/en/Orgenesis-Announces-Reverse-Stock-Split.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- <strong>Orgenesis Inc. (Nasdaq:ORGS) </strong>(“Orgenesis” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company’s common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company’s existing trading symbol “ORGS”.<br></p>]]></content> <dc:identifier>2951240</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Mon, 23 Sep 2024 11:00 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/29/2937765/24226/en/Orgenesis-Announces-Positive-Results-From-a-Real-World-Study-of-ORG-101-CAR-T-Therapy-in-Patients-with-CD19-Acute-Lymphoblastic-Leukemia.html</id> <title type="text">Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia</title> <published>2024-08-29T12:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/29/2937765/24226/en/Orgenesis-Announces-Positive-Results-From-a-Real-World-Study-of-ORG-101-CAR-T-Therapy-in-Patients-with-CD19-Acute-Lymphoblastic-Leukemia.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center"><em>Orgenesis’ CD19 CAR-T therapy, ORG-101, had a complete </em><em>response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study</em></p>]]></content> <dc:identifier>2937765</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Thu, 29 Aug 2024 12:30 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Clinical Study</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/14/2930052/24226/en/Orgenesis-Announces-Strategic-Partnership-with-Harley-Street-Healthcare-Group-to-Launch-a-State-of-the-Art-Longevity-Wellness-Initiative-Globally.html</id> <title type="text">Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally</title> <published>2024-08-14T12:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/14/2930052/24226/en/Orgenesis-Announces-Strategic-Partnership-with-Harley-Street-Healthcare-Group-to-Launch-a-State-of-the-Art-Longevity-Wellness-Initiative-Globally.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture <pre>The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture</pre>]]></content> <dc:identifier>2930052</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Wed, 14 Aug 2024 12:30 GMT</dc:modified> <dc:subject>Partnerships</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Joint Venture</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/08/2927307/24226/en/Orgenesis-Provides-Second-Quarter-2024-Business-Update.html</id> <title type="text">Orgenesis Provides Second Quarter 2024 Business Update</title> <published>2024-08-08T20:05:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/08/2927307/24226/en/Orgenesis-Provides-Second-Quarter-2024-Business-Update.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Acquired GMP-validated platforms for launching proprietary CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes <pre>Acquired GMP-validated platforms for launching proprietary CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes</pre>]]></content> <dc:identifier>2927307</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Thu, 08 Aug 2024 20:05 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/21/2885450/24226/en/Orgenesis-Provides-Business-Update-for-the-First-Quarter-of-2024.html</id> <title type="text">Orgenesis Provides Business Update for the First Quarter of 2024</title> <published>2024-05-21T11:00:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/21/2885450/24226/en/Orgenesis-Provides-Business-Update-for-the-First-Quarter-of-2024.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera <pre>Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera</pre>]]></content> <dc:identifier>2885450</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Tue, 21 May 2024 11:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/04/15/2863210/24226/en/Orgenesis-Provides-Year-End-Business-Update.html</id> <title type="text">Orgenesis Provides Year End Business Update</title> <published>2024-04-15T21:07:16Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/04/15/2863210/24226/en/Orgenesis-Provides-Year-End-Business-Update.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center"><strong><em>M</em></strong><strong><em>ajor transformation underway </em></strong><strong><em>commencing with</em></strong> <strong><em>recent </em></strong><strong><em>acquisition<br></em></strong><strong><em>reasserting</em></strong> <strong><em>full </em></strong><strong><em>ownership and </em></strong><strong><em>control </em></strong><strong><em>over</em></strong><strong><em> Octomera</em></strong></p>]]></content> <dc:identifier>2863210</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Mon, 15 Apr 2024 21:07 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/04/10/2860968/24226/en/Germfree-and-Orgenesis-Announce-Asset-Purchase-and-Strategic-Partnership-Intended-to-Revolutionize-Cell-and-Gene-Therapy-Through-Decentralized-Production-and-Global-Accessibility.html</id> <title type="text">Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility</title> <published>2024-04-10T16:00:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/04/10/2860968/24226/en/Germfree-and-Orgenesis-Announce-Asset-Purchase-and-Strategic-Partnership-Intended-to-Revolutionize-Cell-and-Gene-Therapy-Through-Decentralized-Production-and-Global-Accessibility.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs and its suite of product development and GMP cell processing services. The collaboration’s goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.<br></p>]]></content> <dc:identifier>2860968</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Wed, 10 Apr 2024 16:00 GMT</dc:modified> <dc:subject>Partnerships</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/18/2847794/24226/en/Vered-Caplan-CEO-of-Orgenesis-to-Present-at-the-Bioprocessing-Summit-Europe-Conference.html</id> <title type="text">Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference</title> <published>2024-03-18T12:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/18/2847794/24226/en/Vered-Caplan-CEO-of-Orgenesis-to-Present-at-the-Bioprocessing-Summit-Europe-Conference.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe. The conference, renowned for gathering leading professionals to advance the manufacturing and quality control of biological and genetic therapies, will take place in Barcelona from March 19th to 21st, 2024.<br></p>]]></content> <dc:identifier>2847794</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Mon, 18 Mar 2024 12:30 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/13/2845435/24226/en/Orgenesis-Consortium-Awarded-1-5M-EUR-Grant-from-the-Walloon-Government-in-Belgium-for-EXOFASTTRACK-Project-Dedicated-to-Accelerated-Development-of-Multiple-Therapeutic-Exosomes.html</id> <title type="text">Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes</title> <published>2024-03-13T12:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/13/2845435/24226/en/Orgenesis-Consortium-Awarded-1-5M-EUR-Grant-from-the-Walloon-Government-in-Belgium-for-EXOFASTTRACK-Project-Dedicated-to-Accelerated-Development-of-Multiple-Therapeutic-Exosomes.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that the Company has been awarded a €1.5 million grant from the Walloon government in Belgium for its EXOFASTTRACK project focused on manufacturing, loading, analytical methods and quality control of therapeutic exosomes. Consortium members include: Orgenesis, Cilyx, CMMI, convExYO, EXO Biologics, ExoXpert, Genflow Biosciences, LiveDrop, ULB, UMONS and Xomexbio. This grant is the <a href="https://www.globenewswire.com/Tracker?data=hWdQ_W8aOWxCRB5suHW6cjDAU6AZD-I7VL89YCCuAOCnlj5RIDjLKeITTwcL2h9wLIGSCZ3j61rxT3S3MyTtUxaVKSCtmnKrIFvUJMWZFspVZFgwE2XtiYgmqd5S-ckm" rel="nofollow" target="_blank" title="second">second</a> such project awarded to an Orgenesis consortium by the Walloon Government partnership, ATMP-Partenariat d’Innovation Technologique (ATMP-PIT), in collaboration with BioWin, the health cluster of Wallonia, and the Public service of Wallonia.<br></p>]]></content> <dc:identifier>2845435</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Wed, 13 Mar 2024 12:30 GMT</dc:modified> <dc:subject>Government News</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/04/2839587/24226/en/Orgenesis-Inc-Announces-2-3-Million-Private-Placement.html</id> <title type="text">Orgenesis Inc. Announces $2.3 Million Private Placement</title> <published>2024-03-04T13:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/04/2839587/24226/en/Orgenesis-Inc-Announces-2-3-Million-Private-Placement.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today that it has entered into a definitive securities purchase agreement with certain accredited investors for the sale of 2,272,719 shares of the Company's common stock, warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $2.00 per share in a private placement at a purchase price of $1.03 per share and associated warrants. The warrants are exercisable immediately and expire five years from the date of issuance. The Company expects to receive gross proceeds of approximately $2.3 million before deducting related offering expenses. The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.<br></p>]]></content> <dc:identifier>2839587</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Mon, 04 Mar 2024 13:30 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/02/29/2837975/24226/en/Orgenesis-Consortium-Awarded-2-0M-EUR-Grant-from-Walloon-Government-in-Belgium-for-MAIDAM-AI-Project-for-Monitoring-Decentralized-ATMP-Manufacturing.html</id> <title type="text">Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing</title> <published>2024-02-29T13:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/02/29/2837975/24226/en/Orgenesis-Consortium-Awarded-2-0M-EUR-Grant-from-Walloon-Government-in-Belgium-for-MAIDAM-AI-Project-for-Monitoring-Decentralized-ATMP-Manufacturing.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company’s consortium was awarded a €2.0 million grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing” (MAIDAM). The consortium members include: Orgenesis Services Belgium, Université catholique de Louvain (UCLouvain) / TRusted AI Labs (TRAIL) and DNAlytics. Advanced Therapy Medicinal Products (ATMPs) are among the most innovative and promising biomedicines designed to address unmet medical needs, including cell, gene, exosome and phage therapies.<br></p>]]></content> <dc:identifier>2837975</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Thu, 29 Feb 2024 13:30 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/01/31/2821239/24226/en/Orgenesis-Acquires-Control-of-Octomera-with-the-Goal-of-Progressing-its-Decentralized-Immuno-Oncology-Portfolio-to-Clinic.html</id> <title type="text">Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic</title> <published>2024-01-31T14:15:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/01/31/2821239/24226/en/Orgenesis-Acquires-Control-of-Octomera-with-the-Goal-of-Progressing-its-Decentralized-Immuno-Oncology-Portfolio-to-Clinic.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- <strong>Orgenesis Inc. (Nasdaq:ORGS) </strong> (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners (“Metalmark”), for the acquisition of its approximate 25% stake in Octomera LLC (“Octomera”), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera’s cell processing services, for the three calendar years 2025-2027, along with a portion of the proceeds attributable to Octomera’s cell processing services should there be a change of control in the next 10 years.<br></p>]]></content> <dc:identifier>2821239</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Wed, 31 Jan 2024 14:15 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Mergers and Acquisitions</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/11/14/2780087/24226/en/Orgenesis-Ranked-No-171st-Fastest-Growing-Company-in-North-America-on-the-2023-Deloitte-Technology-Fast-500-TM.html</id> <title type="text">Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM</title> <published>2023-11-14T13:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/11/14/2780087/24226/en/Orgenesis-Ranked-No-171st-Fastest-Growing-Company-in-North-America-on-the-2023-Deloitte-Technology-Fast-500-TM.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Heh7E1DL_ceqRqshJ3od0Qa2s5pe74u08AQ_OZ4300PoOreeta7ic0slfgB4LfsboULGyvJ2vs-hFtgX1jsWUg==" rel="nofollow" target="_blank" title=""><strong>Orgenesis Inc</strong></a><strong>. (NASDAQ: ORGS)</strong> (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it ranked 171 on the <a href="https://www.globenewswire.com/Tracker?data=Ty5hlm1JB-N9QQKUAw9v7DMk1OJA7514yrvzyb9RpCFqQr0iyEIlkBHzls42Ky1E3YwoAuWNICK9-Mm2MKpup-dTwg2BATIGwPe6Rw1SQiBlWax72PonyuQsvy0L4tGqx0u5bN2cnsiMknylM7Quu9u9dCYR72gxgtSKeb2Q0E40dX6ukMQiwum0LRi3-W4KD9-_2edepgvkNM5IJtnm1s_rqQbNjCagEuN2RjLaSp8=" rel="nofollow" target="_blank" title="Deloitte Technology Fast 500">Deloitte Technology Fast 500</a>™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29<sup>th</sup> year.<br></p>]]></content> <dc:identifier>2780087</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Tue, 14 Nov 2023 13:30 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Contests/Awards</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/11/13/2779500/24226/en/Orgenesis-Provides-Business-Update-for-the-Third-Quarter-of-2023.html</id> <title type="text">Orgenesis Provides Business Update for the Third Quarter of 2023</title> <published>2023-11-13T21:15:50Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/11/13/2779500/24226/en/Orgenesis-Provides-Business-Update-for-the-Third-Quarter-of-2023.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Advances rollout of POCare Platform and POCare Therapies <pre>Advances rollout of POCare Platform and POCare Therapies</pre>]]></content> <dc:identifier>2779500</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Mon, 13 Nov 2023 21:16 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/11/08/2776359/24226/en/Orgenesis-Inc-Announces-Pricing-of-1-1-Million-Registered-Direct-Offering.html</id> <title type="text">Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering</title> <published>2023-11-08T14:00:10Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/11/08/2776359/24226/en/Orgenesis-Inc-Announces-Pricing-of-1-1-Million-Registered-Direct-Offering.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- <strong>Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS)</strong>, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.1 million of its common stock and warrants to purchase common stock in a registered direct offering. The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $0.78.<br></p>]]></content> <dc:identifier>2776359</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Wed, 08 Nov 2023 14:04 GMT</dc:modified> <dc:subject>Company Regulatory Filings</dc:subject> <dc:subject>Financing Agreements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/11/02/2772225/24226/en/Orgenesis-Announces-Expanded-Partnership-Between-Octomera-and-UC-Davis-Through-CIRM-Grant-Funding.html</id> <title type="text">Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding</title> <published>2023-11-02T12:00:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/11/02/2772225/24226/en/Orgenesis-Announces-Expanded-Partnership-Between-Octomera-and-UC-Davis-Through-CIRM-Grant-Funding.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">GERMANTOWN, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=C6RGPhr54VOpOkqoaq59l3Elx-ma-Z9FZnIGH1sBthFTe6U5fskbfCXFJTvdzhmCrO79pyvqYqAq_bZwNm5PNw==" rel="nofollow" target="_blank" title=""><u>Orgenesis Inc.</u></a> (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced continued progression of the Point of Care (POCare) network and infrastructure for the advanced therapeutic services and facilities business through its subsidiary Octomera. The teams have been confirmed as an industrial partner to the University of California Davis, a leading academic institution, following a recent California Institute of Regenerative Medicine (CIRM) grant focused on “Creating a Collaborative California Cell and Gene Therapy Manufacturing Network.”<br></p>]]></content> <dc:identifier>2772225</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Thu, 02 Nov 2023 12:00 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> <dc:subject>Partnerships</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/10/31/2769792/24226/en/Orgenesis-Announces-Withdrawal-of-Proposed-Public-Offering.html</id> <title type="text">Orgenesis Announces Withdrawal of Proposed Public Offering</title> <published>2023-10-31T01:30:00Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/10/31/2769792/24226/en/Orgenesis-Announces-Withdrawal-of-Proposed-Public-Offering.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=72vve_iDXEezccaVXBz1c4QAwcFD22ldBJ_hnAzK1XYNCBZS1eRZV3XXkbCflFF0rtt20TgE6gH2I6UWHG1elw==" rel="nofollow" target="_blank" title=""><strong>Orgenesis Inc</strong></a><strong>. (NASDAQ: ORGS)</strong> (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced that it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions.<br></p>]]></content> <dc:identifier>2769792</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Tue, 31 Oct 2023 01:30 GMT</dc:modified> <dc:subject>Management statements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/10/30/2769687/24226/en/Orgenesis-Announces-Proposed-Underwritten-Public-Offering.html</id> <title type="text">Orgenesis Announces Proposed Underwritten Public Offering</title> <published>2023-10-30T20:07:26Z</published> <updated>2024-12-15T07:49:37Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/10/30/2769687/24226/en/Orgenesis-Announces-Proposed-Underwritten-Public-Offering.html" /> <category term="Nasdaq:ORGS" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US68619K1051" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pExrxbF1P9j0pMIwlnh1FaCwv1el05NkqlzAXvezEa4zjGKzG1EkjZECKFFajq7lXOOLv0EbZZt52W47SQ4s7g==" rel="nofollow" target="_blank" title=""><strong>Orgenesis Inc</strong></a><strong>. (NASDAQ: ORGS)</strong> (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it has commenced an underwritten public offering. Orgenesis intends to use the net proceeds from the offering for working capital and general corporate purposes.<br></p>]]></content> <dc:identifier>2769687</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Orgenesis Inc.</dc:contributor> <dc:modified>Mon, 30 Oct 2023 20:08 GMT</dc:modified> <dc:subject>Changes in share capital and votes</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> </entry> </feed>